Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Luke Miels
Pharma
GSK cuts 2024 vaccines sales amid CDC's narrowed RSV policy
Despite limited RSV vaccination policy and disappointing Shingrix sales in Q2, GSK maintained Arexvy's peak sales projection and upped group guidance.
Angus Liu
Jul 31, 2024 10:13am
GSK readopts £3B peak sales estimate for myeloma ADC Blenrep
Jun 17, 2024 3:22pm
GSK reports blockbuster sales for Arexvy in RSV race vs. Pfizer
Jan 31, 2024 9:50am
FDA approves GSK's Jakafi challenger in blood cancer
Sep 15, 2023 4:16pm
GSK's RSV vaccine pegged for blockbuster sales
Apr 26, 2023 10:26am
GSK strikes antifungal deal as deadly pathogen raises alarm
Mar 30, 2023 11:16am
